For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

The global prevalence of MASLD is substantial, with estimates ranging from 30% to 32%, and the incidence of associated conditions like liver ... of fat storage. GLP-1 receptor agonists (GLP ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

GLP-1 receptor agonists emerge as promising therapies for MASLD, addressing metabolic dysfunction and offering potential ...

G-protein coupled receptors regulate hormone secretions in the pancreas. Learn how the complex signaling features ... such as glucagon-like peptide-1, free fatty acids, and catecholamines.

Zepbound (tirzepatide) in an injectable drug that activates receptors in the body for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, researchers said.

Study: Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective. Image Credit: crystal light / Shutterstock ...